Advaxis

Ayala Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, May 23, 2023
Columbia University, Plantar fibromatosis, Quarter, Financial result, Survival, ASCO, American Society of Clinical Oncology, Phase 3, Patient, Annual general meeting, OTCQX, Security (finance), Research, Advaxis, Berlin, Society, PSA, Prostate cancer, Pharmaceutical industry, Medical imaging, Cryptocurrency

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced first-quarter 2023 financial results and provided a corporate update.

Key Points: 
  • REHOVOT, Israel and MONMOUTH JUNCTION, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced first-quarter 2023 financial results and provided a corporate update.
  • For AL101, we expect to gain clarity this year on the development path in recurrent/metastatic adenoid cystic carcinoma (R/M ACC).”
    Completed merger between Ayala Pharmaceuticals Inc. and Advaxis, Inc.
  • Consolidated Financial Results for the Quarter Ended March 31, 2023
    Cash position On March 31, 2023, the consolidated cash and cash equivalents position was $16.8 million.
  • For further details on the Company’s financial results, refer to our quarterly report on Form 10-Q for the three months ended March 31, 2023, filed with the Securities and Exchange Commission.

Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Tuesday, May 16, 2023
Temple University, Drug discovery, Pathology, Bristol Myers Squibb, BD (company), SALT, Bangladesh Technical Education Board, National Cancer Institute, Investigational New Drug, Recursion, National Institute for Health and Care Excellence, Biology, Merck, Advaxis, Cornell University, Pharmaceutical industry, Biochemistry

SALT LAKE CITY, May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has appointed David Mauro, M.D., Ph.D, as its Chief Medical Officer.

Key Points: 
  • SALT LAKE CITY, May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has appointed David Mauro, M.D., Ph.D, as its Chief Medical Officer.
  • “We are incredibly excited to have Dr. Mauro join our team at Recursion at such an important time in the development of our clinical pipeline,” said Chris Gibson, Ph.D., Co-founder and CEO at Recursion.
  • His previous roles include serving as the Chief Medical Officer for Codiak BioSciences, Checkmate Pharmaceutical, Prelude Therapeutics, and Advaxis.
  • Dr. Mauro has also held leadership roles within the clinical and medical affairs teams at Merck, Bristol Myers Squibb, and Becton Dickinson.

Gennao Bio Announces Appointment of Christopher Duke as Chief Executive Officer

Retrieved on: 
Wednesday, April 12, 2023
Oncology, Health, Genetics, General Health, Pharmaceutical, Biotechnology, University, Therapy, Information technology, Bio, Cancer, MBA, Merck & Co., Rutgers University, NPS, Wharton School of the University of Pennsylvania, Dicarboxylic acid, Advaxis, Patient, Chemical engineering, Widener University Commonwealth Law School, Growth, Merck, Amicus Therapeutics, Management

Gennao Bio , a genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced the appointment of Christopher Duke, MBA, M.P.H., as chief executive officer, effective immediately.

Key Points: 
  • Gennao Bio , a genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced the appointment of Christopher Duke, MBA, M.P.H., as chief executive officer, effective immediately.
  • Mr. Duke succeeds executive chairman and founding chief executive officer, Stephen Squinto, M.D., who will transition to a scientific advisor.
  • “Chris has made significant contributions to the growth of Gennao since its inception in 2020, demonstrating strong leadership and strategic agility.
  • He previously served as chief operating officer for Advaxis, Inc., and executive director of international commercial operations for NPS Pharma.

DelveInsight Evaluates a Robust Prostate Cancer Pipeline as 170+ Influential Pharma Players to Set Foot in the Domain

Retrieved on: 
Thursday, February 16, 2023
ZEN, ADC, Plantar fibromatosis, Safety, Eli Lilly and Company, Acquisition, Merck & Co., Lung, BioNTech, CSPC, Clinical trial, Carcinoma, Prostate cancer, Bristol Myers Squibb, Cancer, John Engen, SCNC, Breast, Pain, Regeneron Pharmaceuticals, GT0918, SE, Lymph, Semen, Advaxis, Growth, Society, AstraZeneca, LAS, ASCO, Janssen Pharmaceuticals, PARP, Urination, Human, Blood, United Kingdom, Therapy, Diagnosis, Common, MRI, Patient, PSMA, Ejaculation, Merck, Nivolumab, Tissue, Biopsy, Free trade areas in Europe, Shijiazhuang Pharma Group, Amgen, Urine, Magnetic resonance imaging, Neoplasm, European, TCE, Dairy, Pharmaceutical industry, Medical imaging, Bayer, Pfizer, Pembrolizumab

LAS VEGAS, Feb. 16, 2023 /PRNewswire/ -- DelveInsight's 'Prostate Cancer Pipeline Insight – 2023' report provides comprehensive global coverage of available, marketed, and pipeline prostate cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the prostate cancer pipeline domain.

Key Points: 
  • The rise in the number of cases of prostate cancer has led to growing government funding and rising initiatives by public and private organizations to spread awareness about prostate cancer.
  • The emergence of strong pipeline drugs and the presence of novel prostate cancer treatments are the prominent factors that will escalate the growth rate of the prostate cancer therapeutics market.
  • LAS VEGAS, Feb. 16, 2023 /PRNewswire/ -- DelveInsight's ' Prostate Cancer Pipeline Insight – 2023 ' report provides comprehensive global coverage of available, marketed, and pipeline prostate cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the prostate cancer pipeline domain.
  • DelveInsight's prostate cancer pipeline report depicts a robust space with 170+ active players working to develop 200+ pipeline therapies for prostate cancer treatment.

Ayala Pharmaceuticals Reports Financial Results For the Fiscal Year Ended October 31, 2022

Retrieved on: 
Friday, February 10, 2023
Research, Prostate cancer, Safety, ACC, G&A, Plantar fibromatosis, Fast Track, ESMO, Security (finance), Annual report, PSA, Survival, Poster, Adenoid cystic carcinoma, Patient, ASCO, Form 10-K, FDA, Part, PFS, Columbia University, Advaxis, Pharmaceutical industry, Airline

REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the “Company,” “New Ayala,” “we,” “us” or “our”) (OTCQX: ADXS), a clinical-stage oncology company, today announces financial results for the fiscal year ended October 31, 2022.

Key Points: 
  • REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (f/k/a Advaxis Inc.) (the “Company,” “New Ayala,” “we,” “us” or “our”) (OTCQX: ADXS), a clinical-stage oncology company, today announces financial results for the fiscal year ended October 31, 2022.
  • New Ayala’s Consolidated Financial Results for the Fiscal Year Ended October 31, 2022
    Cash position On October 31, 2022, the consolidated cash and cash equivalents position was $25.2 million.
  • R&D expenses: Research and development expenses for fiscal year 2022 were $7.6 million, compared with $10.6 million for fiscal year 2021.
  • Old Ayala will report consolidated financial results for the full year ended December 31, 2022 (a period completed prior to the merger) on or about March 31, 2023.

Advaxis and Ayala Pharmaceuticals Complete Merger

Retrieved on: 
Thursday, January 19, 2023
Plantar fibromatosis, OTC, Neoplasm, Therapy, AYLA, Patient, OTCQX, Listeria monocytogenes, Interim, Berlin, LM, Pharmaceutical industry, Advaxis

and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes (Lm), today announced the completion of a previously announced merger with Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers.

Key Points: 
  • and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes (Lm), today announced the completion of a previously announced merger with Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers.
  • While the stock will continue to trade on OTC under the symbol ADXS, the merged company will operate under the name Ayala Pharmaceuticals.
  • The merged company will be focused primarily on the development and commercialization of Ayala’s lead program AL102 for the treatment of desmoid tumors.
  • As previously disclosed, the company is seeking to uplist to Nasdaq in the near future, but there is no guarantee that this effort will be successful.

Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer

Retrieved on: 
Thursday, January 12, 2023
Regulatory T cell, Blood, Prostate cancer, Physician, Columbia University Irving Medical Center, Surgeon, Trial of the century, MDSC, Safety, TAAS, Columbia University Vagelos College of Physicians and Surgeons, MD, PSA, Herbert Irving Comprehensive Cancer Center, NK, Columbia University, Patient, Brachytherapy, Abstract, TME, OTCQX, Herbert, Columbia, Medicine, Prostate-specific antigen, LM, Pharmaceutical industry, Advaxis

MONMOUTH JUNCTION, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced an update on the Phase 1 clinical study evaluating ADXS-504, the company’s off-the-shelf neoantigen drug candidate, in patients with biochemically recurrent (early) prostate cancer that is being conducted at Columbia University Irving Medical Center. Karie Runcie, MD, assistant professor of medicine, and Mark N. Stein, MD, associate professor of medicine, in the division of hematology/oncology at Columbia University Vagelos College of Physicians and Surgeons and members of the Herbert Irving Comprehensive Cancer Center, are the study’s principal and senior investigators, respectively.

Key Points: 
  • The study design of this phase 1 open-label dose escalation study for patients in both dose cohorts was presented at the 2022 ASCO Annual Meeting by Dr. Runcie (Abstract #: TPS5115).
  • The trial is currently expanding enrollment at the second dose level by up to six additional patients for a total of nine patients.
  • “We have completed evaluation of the dose-limiting-toxicity period for three patients at the second dose level for this Phase 1 trial of ADXS-504.
  • We look forward to analyzing the composite data to gain further insight into the safety and efficacy of this novel therapy.”

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AYLA, MYOV, USER, AGFS

Retrieved on: 
Sunday, November 20, 2022
Roivant Sciences, Advertising, Advaxis, NYSE, Sale, Fraud, Thoma Bravo, Security (finance)

If you are an Ayala shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Ayala shareholder, click here to learn more about your rights and options .
  • If you are a Myovant shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting

Retrieved on: 
Thursday, November 17, 2022
Marketing, COVID-19, ACC, Science, Tripura Merger Agreement, Cancer, Safety, Biotechnology, Patient, Fast Track, Orphan, Patent, Risk, Failure, Clinical trial, FDA, Pharmaceutical industry, Mergers and acquisitions, Advaxis

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Key Points: 
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
  • These forward-looking statements are based on management's current expectations.
  • New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties.
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors

Retrieved on: 
Wednesday, November 16, 2022
Marketing, COVID-19, ACC, Science, Tripura Merger Agreement, Cancer, Safety, Biotechnology, Patient, Fast Track, Orphan, Patent, Risk, Failure, Clinical trial, FDA, Pharmaceutical industry, Mergers and acquisitions, Advaxis

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Key Points: 
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
  • These forward-looking statements are based on management's current expectations.
  • New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties.
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.